Nature communications · 2026
Monocarboxylate transporter 2 regulates maintenance of myelin and axonal integrity by oligodendrocytes.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Izagirre-Urizar Leire, Mora-Huerta Luna, Soler-Saez Irene, Morales-Gallel Raquel, Masson Mary-Amélie, Ulloa-Navas Maria-Jose, Chara Juan-Carlos, Calovi Stefano, Deboux Cyrille, Merino-Cacho Laura, Andrés-Bilbao Maria, Carretero-Guillén Alejandro, Netzahualcoyotzi Citlalli, Domercq Maria, Zugaza José L, Pellerin Luc, Garcia-Garcia Francisco, Garcia-Verdugo Jose-Manuel, Matute Carlos, Nait-Oumesmar Brahim, Tepavčević Vanja
Аннотация
Myelin alterations, tightly linked to axonal degeneration, are common in neurodegenerative diseases, including multiple sclerosis (MS). However, the metabolic mechanisms that sustain white matter integrity remain elusive. Monocarboxylates are important energy fuels, but their role in myelinating oligodendrocyte function remains unclear. Here, we show that myelinating oligodendrocytes express high affinity monocarboxylate transporter 2 (MCT2), which is downregulated in progressive MS. While deletion of MCT2 in the mouse spinal white matter using oligodendrotropic AAV injection does not affect oligodendrocyte survival, it downregulates lipid synthesis-associated enzymes and increases inflammation, leading to a failure of myelin maintenance. These changes, not evidenced in AAV-control mice that only show mild inflammation, are accompanied by axonal upregulation of lactate dehydrogenase A and injury, effects alleviated by ketogenic diet. Therefore, our findings show that oligodendroglial MCT2 regulates myelin maintenance and axonal support under mild inflammation. This appears disrupted in progressive MS but might be compensated for by specific metabolic therapies to preserve white matter integrity.